Oncolytic viruses and their application to cancer immunotherapy

Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain

Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection

TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host